Is it the time for Hepatitis E virus (HEV) Testing for Blood Donors in Qatar? by Nasrallah, Gheyath et al.
This abstract is available through QScience.com
ARC '16
Cite this article as: Nasrallah G, Hedaya L, Ali F, Alhusaini A, Al Absi E, Sami M, Taleb S. (2016). Is it the time for Hepatitis 
E virus (HEV) Testing for Blood Donors in Qatar? Qatar Foundation Annual Research Conference Proceedings 2016: 
HBSP2838 http://dx.doi.org/10.5339/qfarc.2016.HBSP2838.
Health and Biomedical Pillar
http://dx.doi.org/10.5339/qfarc.2016.HBSP2838
Is it the time for Hepatitis E virus (HEV) Testing for Blood Donors in Qatar?
Gheyath Nasrallah, Laila Hedaya, Fatima Ali, Abdellatif Alhusaini, Enas Al Absi, Mariam Sami, Sara Taleb
Qatar University, QA
Email: gheyath.nasrallah@qu.edu.qa
Background
HEV is the etiologic agent of acute hepatitis E. Although HEV usually causes a self-limiting infection, the disease may 
develop into a chronic or fulminant form of Hepatitis. Sporadic HEV infections spread in several developed countries; 
however, outbreaks usually occur in regions where sanitation is low, in particular, in developing countries where 
water flooding frequently occurs. In addition, religious background, life style, hygienic practices, and the economic 
status have been linked to HEV infection. Fecal-oral is the established route of transmission, however, infections 
through blood transfusion were recently documented in many developed and developing countries. This recent 
finding raises the question: is there is a need for HEV screening prior transfusion or transplantation? Studies related 
to this issue, in the Middle East are scarce. Although the CDC HEV epidemiological map, classifies the Arabian Gulf 
countries including Qatar as endemic or highly endemic, to the best of our knowledge, no HEV population –based 
epidemiological study were conducted in Qatar. HEV infection is usually detected using IgM and IgG serological tests 
and confirmed by molecular tests for detection of viral RNA. Yet, commercially available HEV serological kits are not 
validated, and needs further investigation.
Aim and Methods
Qatar has a diverse population due to increased number of expatriate workers. The majority of these workers usually 
come from low economic status countries that are highly endemic for HEV such as Egypt, Sudan, India and other 
South East Asian countries. This fact highlights the need for an epidemiological study concerning HEV prevalence 
in Qatar. Accordingly, we hypothesize that HEV seroprevalence in Qatar is elevated, and therefore, there is a risk 
of HEV transfusion transmitted infections in Qatar’s blood bank. The goals of this study are (i) to investigate the 
seroprevalence of HEV (anti-HEV IgM/IgG) among healthy blood donors in Qatar and (ii) to evaluate performance 
of 5 common commercially available anti-HEV IgG and IgM kits (manufactures by 
Wantai Biological Pharmacy, China; MP Biomedicals & Diagnostic Automation, USA; and 
Euroimmun & Mikrogen Diagnostik; Germany). All of these kits are solid phase ELISA based, 
except the Mikrogen kit which is immunoblot based. A total of 4056 blood donor samples 
were collected from healthy blood donors visited the Blood Donation Center at Hamad 
Medical Corporation (HMC) over a period of three years (2013-2015). For seroprevalence 
study, plasma were separated and tested for the presence of HEV IgG and IgM using Wantai 
ELISA kit, which, is the most commonly used serological kit according to literature. For 
statistical analysis, chi-square test was performed and results were considered statistically 
significant when the p-value were less than 0.05.
Results
Out of total 4056 analyzed samples, almost one quarter of blood donors, 829 (20.45%) 
tested positive for anti-HEV IgG and only 21 (0.52%) blood samples tested positive for anti-
HEV IgM. As shown in figure 1, HEV seroprevalence was associated with age group (P 
